{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:05:32Z","timestamp":1790251532817,"version":"4.1.0"},"reference-count":105,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Recombinant human erythropoietin (rHuEpo) is widely used to treat anaemia in patients with cancer. Concerns regarding its safety arose from early experimental studies suggesting erythropoietin receptor (EpoR) expression in tumour cells and potential pro-tumorigenic effects. However, many of these findings were generated using non-specific antibodies or incomplete molecular validation, leading to uncertainty about the clinical relevance of EpoR in oncology. A structured narrative review was conducted through a PubMed\/MEDLINE search (1990\u20132025) using predefined terms related to EpoR and cancer. Additional references were identified via citation tracking. Studies evaluating EpoR expression in tumourderived cell lines or human tumour tissues or exploring the clinical implications of rHuEpo therapy were included. A bibliometric analysis was also performed to contextualize historical trends in publication volume. Early studies reported widespread EpoR expression in cancer models; however, most used non-validated polyclonal antibodies and lacked molecular confirmation. When more rigorous approaches were adopted, EpoR detection in tumours was inconsistent or negligible. Clinical trials reporting adverse outcomes with rHuEpo were largely conducted before current regulatory restrictions, used variable haemoglobin targets or enrolled patients who would not be eligible for treatment today. Current evidence does not support a biologically meaningful role of EpoR in solid tumours. When used within approved indications and modern safety guidance, rHuEpo has not been consistently associated with tumour progression or reduced survival. Continued methodological rigour is essential to clarify remaining uncertainties and optimize rHuEpo use in oncology.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-recombinant-human-erythropoietin-therapy-in-patients-with-cancer-efficacy-risks-and-the-controversy-of-epor-expression<\/jats:p>","DOI":"10.7573\/dic.2025-12-2","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T13:23:33Z","timestamp":1778160213000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Recombinant human erythropoietin therapy in patients with cancer: efficacy, risks and the controversy of EpoR expression"],"prefix":"10.7573","volume":"15","author":[{"given":"Alessio","family":"Sturiale","sequence":"first","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetto","family":"Sessa","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Martina","sequence":"additional","affiliation":[{"name":"D. Camberlingo Hospital, Francavilla Fontana, Brindisi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Maltese","sequence":"additional","affiliation":[{"name":"San Giovanni di Dio Hospital, Agrigento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Campo","sequence":"additional","affiliation":[{"name":"Papardo Hospital, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Crasc\u00ec","sequence":"additional","affiliation":[{"name":"Centro Nefrologico, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Galeano","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Alessandrello","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Zuppardo","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Scollo","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunata","family":"Zirino","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Distefano","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tigano","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giglio","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ficara","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Maria","family":"Messina","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Stella","family":"Musumeci","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cicero","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Dimartino","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenza","family":"Rauseo","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Morale","sequence":"additional","affiliation":[{"name":"Maggiore \u201cNino Baglieri\u201d Hospital, Modica, Ragusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tYoon D, Pastore YD, Divoky V, et al. Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J Biol Chem. 2006;281(35):25703\u201325711. https:\/\/doi. org\/10.1074\/jbc.M602329200","DOI":"10.1074\/jbc.M602329200"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tCerami A, Brines ML, Ghezzi P, Cerami CJ. Effects of epoetin alfa on the central nervous system. Semin Oncol. 2001;28(2 Suppl. 8):66\u201370. https:\/\/doi.org\/10.1016\/s0093-7754(01)90216-7","DOI":"10.1053\/sonc.2001.25401"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tSir\u00e9n AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001;98(7):4044\u20134049. https:\/\/doi.org\/10.1073\/pnas.051606598","DOI":"10.1073\/pnas.051606598"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tSanthanam AVR, Smith LA, Nath KA, Katusic ZS. In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries. Am J Physiol Heart Circ Physiol. 2006;291(2):H781\u2013786. https:\/\/doi.org\/10.1152\/ ajpheart.00045.2006","DOI":"10.1152\/ajpheart.00045.2006"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tSepodes B, Maio R, Pinto R, et al. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int. 2006;19(11):919\u2013926. https:\/\/doi.org\/10.1111\/j.1432-2277.2006.00366.x","DOI":"10.1111\/j.1432-2277.2006.00366.x"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tMatsumoto M, Makino Y, Tanaka T, et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol. 2003;14(7):1825\u20131832. https:\/\/doi.org\/10.1097\/01. asn.0000074239.22357.06","DOI":"10.1097\/01.ASN.0000074239.22357.06"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tLivnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999;283(5404):987\u2013990. https:\/\/doi.org\/10.1126\/ science.283.5404.987","DOI":"10.1126\/science.283.5404.987"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tBrines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA. 2004;101(41):14907\u201314912. https:\/\/doi.org\/10.1073\/ pnas.0406491101","DOI":"10.1073\/pnas.0406491101"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tWu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83(1):59\u201367. https:\/\/doi.org\/10.1016\/0092- 8674(95)90234-1","DOI":"10.1016\/0092-8674(95)90234-1"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tZhao W, Kitidis C, Fleming MD, Lodish HF, Ghaffari S. Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase\/AKT signaling pathway. Blood. 2006;107(3):907\u2013915. https:\/\/doi.org\/10.1182\/blood-2005-06-2516","DOI":"10.1182\/blood-2005-06-2516"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tEchigoya MH, Obikane K, Nakashima T, Sasaki S. Glomerular localization of erythropoietin receptor mRNA and protein in neonatal and mature mouse kidney. Nephron Exp Nephrol. 2005;100(1):e21\u201329. https:\/\/doi. org\/10.1159\/000084109","DOI":"10.1159\/000084109"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tWestenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999;55(3):808\u2013820. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.055003808.x","DOI":"10.1046\/j.1523-1755.1999.055003808.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tRibatti D, Poliani PL, Longo V, Mangieri D, Nico B, Vacca A. Erythropoietin\/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology. 2007;50(5):636\u2013641. https:\/\/doi.org\/10.1111\/j.1365- 2559.2007.02653.x","DOI":"10.1111\/j.1365-2559.2007.02653.x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tRibatti D, Marzullo A, Gentile A, et al. Erythropoietin\/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology. 2007;50(5):591\u2013596. https:\/\/doi.org\/10.1111\/j.1365- 2559.2007.02654.x","DOI":"10.1111\/j.1365-2559.2007.02654.x"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tWestphal G, Niederberger E, Blum C, et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori. 2002;88(2):150\u2013159. https:\/\/doi.org\/10.1177\/030089160208800214","DOI":"10.1177\/030089160208800214"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tBohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336\u20131351. https:\/\/doi.org\/10.1200\/ JCO.18.02142","DOI":"10.1200\/JCO.18.02142"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tPregi N, Vittori D, P\u00e9rez G, Leir\u00f3s CP, Nesse A. Effect of erythropoietin on staurosporine-induced apoptosis and differentiation of SH-SY5Y neuroblastoma cells. Biochim Biophys Acta. 2006;1763(2):238\u2013246. https:\/\/doi. org\/10.1016\/j.bbamcr.2005.12.011","DOI":"10.1016\/j.bbamcr.2005.12.011"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tElliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood. 2006;107(5):1892\u20131895. https:\/\/doi.org\/10.1182\/blood-2005-10-4066","DOI":"10.1182\/blood-2005-10-4066"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tLeyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23(25):5960\u20135972. https:\/\/doi.org\/10.1200\/JCO.2005.06.150","DOI":"10.1200\/JCO.2005.06.150"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tLittlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19(11):2865\u20132874. https:\/\/doi.org\/10.1200\/ JCO.2001.19.11.2865","DOI":"10.1200\/JCO.2001.19.11.2865"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tDemetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998;16(10):3412\u20133425. https:\/\/doi.org\/10.1200\/JCO.1998.16.10.3412","DOI":"10.1200\/JCO.1998.16.10.3412"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tOsterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol. 2002;20(10):2486\u20132494. https:\/\/doi. org\/10.1200\/JCO.2002.08.131","DOI":"10.1200\/JCO.2002.08.131"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tVansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94(16):1211\u20131220. https:\/\/ doi.org\/10.1093\/jnci\/94.16.1211","DOI":"10.1093\/jnci\/94.16.1211"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tBoogaerts M, Coiffier B, Kainz C, Epoetin beta QOL working group. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer. 2003;88(7):988\u2013995. https:\/\/doi.org\/10.1038\/sj.bjc.6600801","DOI":"10.1038\/sj.bjc.6600801"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tCrawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95(4):888\u2013895. https:\/\/doi.org\/10.1002\/cncr.10763","DOI":"10.1002\/cncr.10763"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tChang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2005;23(12):2597\u2013 2605. https:\/\/doi.org\/10.1200\/JCO.2004.12.027","DOI":"10.1200\/JCO.2004.12.027"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tLeyland-Jones B, Bondarenko I, Nemsadze G, et al. A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J Clin Oncol. 2016;34(11):1197\u20131207. https:\/\/doi.org\/10.1200\/JCO.2015.63.5649","DOI":"10.1200\/JCO.2015.63.5649"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tAlbain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest oncology group experience. J Clin Oncol. 1991;9(9):1618\u20131626. https:\/\/doi.org\/10.1200\/ JCO.1991.9.9.1618","DOI":"10.1200\/JCO.1991.9.9.1618"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tDunst J, Kuhnt T, Strauss HG, et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys. 2003;56(3):778\u2013787. https:\/\/doi.org\/10.1016\/ s0360-3016(03)00123-8","DOI":"10.1016\/S0360-3016(03)00123-8"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tAlbain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest oncology group experience. Chest. 1991;99(6):1425\u20131432. https:\/\/doi.org\/10.1378\/chest.99.6.1425","DOI":"10.1378\/chest.99.6.1425"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tHaensgen G, Krause U, Becker A, et al. Tumor hypoxia, p53, and prognosis in cervical cancers. Int J Radiat Oncol Biol Phys. 2001;50(4):865\u2013872. https:\/\/doi.org\/10.1016\/s0360-3016(01)01523-1","DOI":"10.1016\/S0360-3016(01)01523-1"},{"key":"ref31","unstructured":"32.\tKelleher DK, Mattheinsen U, Thews O, Vaupel P. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res. 1996;56(20):4728\u20134734."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tSilver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol. 1999;73(2):280\u2013284. https:\/\/doi. org\/10.1006\/gyno.1999.5368","DOI":"10.1006\/gyno.1999.5368"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tFyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998;48(2):149\u2013156. https:\/\/doi.org\/10.1016\/s0167-8140(98)00044-9","DOI":"10.1016\/S0167-8140(98)00044-9"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tTeicher BA. Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol Oncol Clin North Am. 1995;9(2):475\u2013506.","DOI":"10.1016\/S0889-8588(18)30105-9"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tSupavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P. Differential gene expression following early renal ischemia\/reperfusion. Kidney Int. 2003;63(5):1714\u20131724. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00928.x","DOI":"10.1046\/j.1523-1755.2003.00928.x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tYoshida T, Kurella M, Beato F, et al. Monitoring changes in gene expression in renal ischemia-reperfusion in the rat. Kidney Int. 2002;61(5):1646\u20131654. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00341.x","DOI":"10.1046\/j.1523-1755.2002.00341.x"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tSavonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist. 2006;11(2):206\u2013216. https:\/\/doi.org\/10.1634\/theoncologist.11-2-206","DOI":"10.1634\/theoncologist.11-2-206"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tBelenkov AI, Shenouda G, Rizhevskaya E, et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther. 2004;3(12):1525\u20131532.","DOI":"10.1158\/1535-7163.1525.3.12"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.\tAnagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA. 1994;91(9):3974\u20133978. https:\/\/doi.org\/10.1073\/pnas.91.9.3974","DOI":"10.1073\/pnas.91.9.3974"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.\tRibatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999;93(8):2627\u20132636.","DOI":"10.1182\/blood.V93.8.2627"},{"key":"ref41","unstructured":"42.\tRosti V, Pedrazzoli P, Ponchio L, et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica. 1993;78(4):208\u2013212."},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tSelzer E, Wacheck V, Kodym R, et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res. 2000;10(5):421\u2013426. https:\/\/doi.org\/10.1097\/00008390-200010000-00003","DOI":"10.1097\/00008390-200010000-00003"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tKumar SM, Yu H, Fong D, Acs G, Xu X. Erythropoietin activates the phosphoinositide 3-kinase\/Akt pathway in human melanoma cells. Melanoma Res. 2006;16(4):275\u2013283. https:\/\/doi.org\/10.1097\/01.cmr.0000222594.60611.c3","DOI":"10.1097\/01.cmr.0000222594.60611.c3"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tKumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol. 2005;166(3):823\u2013830. https:\/\/doi.org\/10.1016\/S0002-9440(10)62303-6","DOI":"10.1016\/S0002-9440(10)62303-6"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.\tPajonk F, Weil A, Sommer A, Suwinski R, Henke M. The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene. 2004;23(55):8987\u20138991. https:\/\/doi.org\/10.1038\/sj.onc.1208140","DOI":"10.1038\/sj.onc.1208140"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tCarvalho G, Lefaucheur C, Cherbonnier C, et al. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene. 2005;24(5):737\u2013745. https:\/\/doi.org\/10.1038\/sj.onc.1208205","DOI":"10.1038\/sj.onc.1208205"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tJolly C, Usson Y, Morimoto RI. Rapid and reversible relocalization of heat shock factor 1 within seconds to nuclear stress granules. Proc Natl Acad Sci USA. 1999;96(12):6769\u20136774. https:\/\/doi.org\/10.1073\/pnas.96.12.6769","DOI":"10.1073\/pnas.96.12.6769"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tMinet E, Michel G, Remacle J, Michiels C. Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (review). Int J Mol Med. 2000;5(3):253\u2013259. https:\/\/doi. org\/10.3892\/ijmm.5.3.253","DOI":"10.3892\/ijmm.5.3.253"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.\tWang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281(5383):1680\u20131683. https:\/\/doi.org\/10.1126\/ science.281.5383.1680","DOI":"10.1126\/science.281.5383.1680"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.\tSmahi A, Courtois G, Rabia SH, et al. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet. 2002;11(20):2371\u20132375. https:\/\/doi.org\/10.1093\/hmg\/11.20.2371","DOI":"10.1093\/hmg\/11.20.2371"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.\tBatra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest. 2003;83(10):1477\u20131487. https:\/\/doi.org\/10.1097\/01.lab.0000090156.94795.48","DOI":"10.1097\/01.LAB.0000090156.94795.48"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.\tAcs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol. 2003;162(6):1789\u20131806. https:\/\/doi.org\/10.1016\/S0002-9440(10)64314-3","DOI":"10.1016\/S0002-9440(10)64314-3"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.\tUm M, Lodish HF. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. J Biol Chem. 2006;281(9):5648\u20135656. https:\/\/doi. org\/10.1074\/jbc.M510943200","DOI":"10.1074\/jbc.M510943200"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.\tLai SY, Childs EE, Xi S, et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 2005;24(27):4442\u20134449. https:\/\/doi.org\/10.1038\/ sj.onc.1208635","DOI":"10.1038\/sj.onc.1208635"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.\tLaMontagne KR, Butler J, Marshall DJ, et al. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006;5(2):347\u2013355. https:\/\/doi.org\/10.1158\/1535-7163. MCT-05-0203","DOI":"10.1158\/1535-7163.MCT-05-0203"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57.\tHale SA, Wong C, Lounsbury KM. Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells. Gynecol Oncol. 2006;100(1):14\u201319. https:\/\/doi.org\/10.1016\/j.ygyno.2005.08.056","DOI":"10.1016\/j.ygyno.2005.08.056"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58.\tMcBroom JW, Acs G, Rose GS, Krivak TC, Mohyeldin A, Verma A. Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol. 2005;99(3):571\u2013577. https:\/\/doi.org\/10.1016\/j.ygyno.2005.06.038","DOI":"10.1016\/j.ygyno.2005.06.038"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59.\tAcs G, Chen M, Xu X, Acs P, Verma A, Koch CJ. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett. 2004;214(2):243\u2013251. https:\/\/doi.org\/10.1016\/j. canlet.2004.04.027","DOI":"10.1016\/j.canlet.2004.04.027"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60.\tWestenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000;58(2):647\u2013657. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00211.x","DOI":"10.1046\/j.1523-1755.2000.00211.x"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.\tYasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis. 2003;24(6):1021\u20131029. https:\/\/doi.org\/10.1093\/carcin\/bgg060","DOI":"10.1093\/carcin\/bgg060"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.\tFarrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist. 2004;9(Suppl. 5):18\u201330. https:\/\/doi.org\/10.1634\/theoncologist.9-90005-18","DOI":"10.1634\/theoncologist.9-90005-18"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63.\tJohnson DW, Forman C, Vesey DA. Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology. 2006;11(4):306\u2013312. https:\/\/doi.org\/10.1111\/j.1440-1797.2006.00585.x","DOI":"10.1111\/j.1440-1797.2006.00585.x"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64.\tAcs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer. 2002;95(5):969\u2013981. https:\/\/doi.org\/10.1002\/cncr.10787","DOI":"10.1002\/cncr.10787"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65.\tRibatti D, Marzullo A, Nico B, Crivellato E, Ria R, Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology. 2003;42(3):246\u2013250. https:\/\/doi.org\/10.1046\/j.1365-2559.2003.01581.x","DOI":"10.1046\/j.1365-2559.2003.01581.x"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"66.\tArcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res. 2005;11(1):20\u201327.","DOI":"10.1158\/1078-0432.20.11.1"},{"key":"ref66","unstructured":"67.\tEccles TG, Patel A, Verma A, et al. Erythropoietin and the erythropoietin receptor are expressed by papillary thyroid carcinoma from children and adolescents. Expression of erythropoietin receptor might be a favorable prognostic indicator. Ann Clin Lab Sci. 2003;33(4):411\u2013422."},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"68.\tMohyeldin A, Lu H, Dalgard C, et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia. 2005;7(5):537\u2013543. https:\/\/doi.org\/10.1593\/neo.04685","DOI":"10.1593\/neo.04685"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"69.\tHoogsteen IJ, Peeters WJM, Marres HAM, et al. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas. Radiother Oncol. 2005;76(2):213\u2013218. https:\/\/doi.org\/10.1016\/j.radonc.2005.06.030","DOI":"10.1016\/j.radonc.2005.06.030"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"70.\tWinter SC, Shah KA, Campo L, et al. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Clin Cancer Res. 2005;11(21):7614\u20137620. https:\/\/doi. org\/10.1158\/1078-0432.CCR-05-1097","DOI":"10.1158\/1078-0432.CCR-05-1097"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"71.\tHenke M, Laszig R, R\u00fcbe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362(9392):1255\u20131260. https:\/\/doi. org\/10.1016\/S0140-6736(03)14567-9","DOI":"10.1016\/S0140-6736(03)14567-9"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"72.\tHenke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol. 2006;24(29):4708\u20134713. https:\/\/doi.org\/10.1200\/JCO.2006.06.2737","DOI":"10.1200\/JCO.2006.06.2737"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"73.\tMittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA. 2001;98(9):5181\u20135186. https:\/\/doi.org\/10.1073\/pnas.081275298","DOI":"10.1073\/pnas.081275298"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"74.\tT\u00f3v\u00e1ri J, Gilly R, R\u00e1s\u00f3 E, et al. Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res. 2005;65(16):7186\u20137193. https:\/\/doi. org\/10.1158\/0008-5472.CAN-04-2498","DOI":"10.1158\/0008-5472.CAN-04-2498"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"75.\tFeldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate. 2006;66(2):135\u2013145. https:\/\/doi. org\/10.1002\/pros.20310","DOI":"10.1002\/pros.20310"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"76.\tHardee ME, Rabbani ZN, Arcasoy MO, et al. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther. 2006;5(2):356\u2013361. https:\/\/doi. org\/10.1158\/1535-7163.MCT-05-0196","DOI":"10.1158\/1535-7163.MCT-05-0196"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"77.\tLester RD, Jo M, Campana WM, Gonias SL. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK\/ mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem. 2005;280(47):39273\u201339277. https:\/\/doi.org\/10.1074\/jbc.M509446200","DOI":"10.1074\/jbc.M509446200"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"78.\tChiu DKC, Zhang X, Cheng BYL, et al. Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity. Science. 2025;388(6745):eadr3026. https:\/\/doi.org\/10.1126\/science.adr3026","DOI":"10.1126\/science.adr3026"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"79.\tCao Y, Lathia JD, Eyler CE, et al. Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer. 2010;1(1):50\u201361. https:\/\/doi.org\/10.1177\/1947601909356352","DOI":"10.1177\/1947601909356352"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"80.\tNavone SE, Marfia G, Guarnaccia L, et al. Revealing erythropoietin variant EV-3 as novel driving force and immunotherapeutic target in human glioblastoma. J Exp Clin Cancer Res. 2025;45(1):94. https:\/\/doi.org\/10.1186\/ s13046-025-03620-3","DOI":"10.1186\/s13046-025-03620-3"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"81.\tT\u00f3thov\u00e1 Z, \u0160emel\u00e1kov\u00e1 M, Bhide K, et al. Differentially expressed genes induced by erythropoietin receptor overexpression in rat mammary adenocarcinoma RAMA 37-28 cells. Int J Mol Sci. 2023;24(10):8482. https:\/\/doi. org\/10.3390\/ijms24108482","DOI":"10.3390\/ijms24108482"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"82.\tBuemi M, Galeano M, Sturiale A, et al. Recombinant human erythropoietin stimulates angiogenesis and healing of ischemic skin wounds. Shock. 2004;22(2):169\u2013173. https:\/\/doi.org\/10.1097\/01.shk.0000133591.47776.bd","DOI":"10.1097\/01.shk.0000133591.47776.bd"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"83.\tZhang X, McGinnis CS, Yu G, et al. Erythropoietin receptor on cDC1s dictates immune tolerance. Nature. 2026;650(8101):470\u2013480. https:\/\/doi.org\/10.1038\/s41586-025-09824-z","DOI":"10.1038\/s41586-025-09824-z"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"84.\t\u010coki\u0107 BBB, Radulovi\u0107 SB, Suboti\u010dki T, et al. Regulation of erythropoietin activity in clear renal cell carcinoma. Int J Mol Sci. 2025;26(8):3777. https:\/\/doi.org\/10.3390\/ijms26083777","DOI":"10.3390\/ijms26083777"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"85.\tMenon J, Ahmed R, Aslam M, Singh R, Friedlander P, Aljitawi O. Abstract 2659: erythropoietin stimulation in BRAF mutated metastatic melanoma confers a highly proliferative and invasive phenotype. Cancer Research. 2025;85(8 Suppl. 1):2659\u20132659. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-2659","DOI":"10.1158\/1538-7445.AM2025-2659"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"86.\tRizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28(33):4996\u20135010. https:\/\/doi.org\/10.1200\/JCO.2010.29.2201","DOI":"10.1200\/JCO.2010.29.2201"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"87.\tGriffiths EA, Roy V, Alwan L, et al. NCCN guidelines\u00ae insights: hematopoietic growth factors, version 1.2022. J Natl Compr Canc Netw. 2022;20(5):436\u2013442. https:\/\/doi.org\/10.6004\/jnccn.2022.0026","DOI":"10.6004\/jnccn.2022.0026"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"88.\tAapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl. 4):iv96\u2013iv110. https:\/\/doi.org\/10.1093\/annonc\/mdx758","DOI":"10.1093\/annonc\/mdx758"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"89.\tThomaidis T, Weinmann A, Sprinzl M, et al. Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. Int J Clin Oncol. 2014;19(2):288\u2013296. https:\/\/doi. org\/10.1007\/s10147-013-0544-7","DOI":"10.1007\/s10147-013-0544-7"},{"key":"ref89","unstructured":"90.\tAcs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61(9):3561\u20133565."},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"91.\tArcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun. 2003;307(4):999\u20131007. https:\/\/doi.org\/10.1016\/s0006-291x(03)01303-2","DOI":"10.1016\/S0006-291X(03)01303-2"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"92.\tCervi D, Truong AHL, Lee JS, et al. Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib. Oncogene. 2004;23(13):2305\u20132314. https:\/\/doi.org\/10.1038\/sj.onc.1207400","DOI":"10.1038\/sj.onc.1207400"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"93.\tDunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR. Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis. 2006;3(1-2):94\u2013100. https:\/\/doi.org\/10.1159\/000092099","DOI":"10.1159\/000092099"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"94.\tDunlop EA, Maxwell AP, Lappin TRJ. Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma. Stem Cells. 2007;25(2):380\u2013384. https:\/\/doi.org\/10.1634\/stemcells.2006-0452","DOI":"10.1634\/stemcells.2006-0452"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"95.\tMoucadel V, Constantinescu SN. Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors. J Biol Chem. 2005;280(14):13364\u201313373. https:\/\/doi.org\/10.1074\/jbc.M407326200","DOI":"10.1074\/jbc.M407326200"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"96.\tYates CM, Patel A, Oakley K, Helms A, Tuttle RM, Francis GL. Erythropoietin in thyroid cancer. J Endocrinol Invest. 2006;29(4):320\u2013329. https:\/\/doi.org\/10.1007\/BF03344103","DOI":"10.1007\/BF03344103"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"97.\tAcs G, Xu X, Chu C, Acs P, Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer. 2004;100(11):2376\u20132386. https:\/\/doi.org\/10.1002\/cncr.20244","DOI":"10.1002\/cncr.20244"},{"key":"ref97","unstructured":"98.\tChan CC, Chew EY, Shen D, Hackett J, Zhuang Z. Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease. Mol Vis. 2005;11:697\u2013704."},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"99.\tDagnon K, Pacary E, Commo F, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res. 2005;11(3):993\u2013999.","DOI":"10.1158\/1078-0432.993.11.3"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"100.\tDillard DG, Venkatraman G, Cohen C, Delgaudio J, Gal AA, Mattox DE. Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. Acta Otolaryngol. 2001;121(2):149\u2013152. https:\/\/doi. org\/10.1080\/000164801300043262","DOI":"10.1080\/000164801300043262"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"101.\tLee YS, Vortmeyer AO, Lubensky IA, et al. Coexpression of erythropoietin and erythropoietin receptor in von Hippel- Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res. 2005;11(3):1059\u20131064.","DOI":"10.1158\/1078-0432.1059.11.3"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"102.\tPollio F, Staibano S, Mansueto G, et al. Erythropoietin and erythropoietin receptor system in a large uterine myoma of a patient with myomatous erythrocytosis syndrome: possible relationship with the pathogenesis of unusual tumor size. Hum Pathol. 2005;36(1):120\u2013127. https:\/\/doi.org\/10.1016\/j.humpath.2004.10.009","DOI":"10.1016\/j.humpath.2004.10.009"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"103.\tShenouda G, Mehio A, Souhami L, et al. Erythropoietin receptor expression in biopsy specimens from patients with uterine cervix squamous cell carcinoma. Int J Gynecol Cancer. 2006;16(2):752\u2013756. https:\/\/doi.org\/10.1111\/j.1525- 1438.2006.00357.x","DOI":"10.1136\/ijgc-00009577-200603000-00045"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"104.\tVogel TWA, Brouwers FM, Lubensky IA, et al. Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas. J Clin Endocrinol Metab. 2005;90(6):3747\u20133751. https:\/\/doi.org\/10.1210\/jc.2004-1899","DOI":"10.1210\/jc.2004-1899"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"105.\tVogel TWA, Vortmeyer AO, Lubensky IA, et al. Coexpression of erythropoietin and its receptor in endolymphatic sac tumors. J Neurosurg. 2005;103(2):284\u2013288. https:\/\/doi.org\/10.3171\/jns.2005.103.2.0284","DOI":"10.3171\/jns.2005.103.2.0284"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/05\/dic.2025-12-2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:12:14Z","timestamp":1790248334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/recombinant-human-erythropoietin-therapy-in-patients-with-cancer-efficacy-risks-and-the-controversy-of-epor-expression\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":105,"URL":"https:\/\/doi.org\/10.7573\/dic.2025-12-2","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"dic.2025-12-2"}}